Baudax Bio to Present at Oppenheimer Fall Healthcare Life Sciences & Medtech Summit

Rhea-AI Summary

Baudax Bio, Inc. (NASDAQ: BXRX) announced that CEO Gerri Henwood will present at the Oppenheimer Fall Healthcare Life Sciences & Medtech Summit on September 22, 2020, at 3:20 p.m. ET. A live webcast will be available on Baudax Bio's website, with a replay accessible for 30 days post-event. The company focuses on therapeutics for acute care, having launched its product ANJESO® in June 2020. ANJESO, approved by the FDA for moderate to severe pain management, is a non-opioid IV NSAID that potentially addresses common opioid-related issues.

MALVERN, Pa., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced Gerri Henwood, the Company’s President and Chief Executive Officer, will present at the Oppenheimer Fall Healthcare Life Sciences & Medtech Summit on Tuesday, September 22, 2020 at 3:20 p.m. ET.

A live webcast of the presentation will be available on the “Presentations” page within the Investors section of the Baudax Bio website at https://www.baudaxbio.com/news-and-investors. A replay will be available on the Baudax Bio website for a period of 30 days following the event.

About Baudax Bio

Baudax Bio is a pharmaceutical company focused on therapeutics for acute care settings. The launch of the Company’s first commercial product, ANJESO^®, began in June of 2020. Baudax’s New Drug Application for ANJESO was approved by FDA on February 20, 2020 for the management the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. ANJESO is a once daily IV NSAID with preferential Cox-2 activity, which has successfully completed three Phase III clinical trials, including two pivotal efficacy trials, a large double-blind Phase III safety trial and other studies for the management of moderate to severe pain. As a non-opioid, IV meloxicam has the potential to overcome many of the issues associated with commonly prescribed opioid therapeutics, including respiratory depression, constipation, excessive nausea and vomiting, as well as having no addictive potential while maintaining meaningful analgesic effects for relief of pain. For more information please visit www.baudaxbio.com.

CONTACT:

Investor Relations Contact:
Argot Partners
Sam Martin / Claudia Styslinger
(212) 600-1902
sam@argotpartners.com
claudia@argotpartners.com

Baudax Bio, Inc.
Ryan D. Lake
(484) 395-2436
rlake@baudaxbio.com

Media Contact:
Argot Partners
David Rosen
(212) 600-1902
david.rosen@argotpartners.com

FAQ

What is Baudax Bio's upcoming event date and details involving stock symbol BXRX?

Baudax Bio's CEO Gerri Henwood will present at the Oppenheimer Fall Healthcare Life Sciences & Medtech Summit on September 22, 2020, at 3:20 p.m. ET.

Where can I watch the Baudax Bio BXRX presentation live?

You can watch the live webcast of Baudax Bio's presentation on their 'Presentations' page within the Investors section of their website.

What product did Baudax Bio launch in June 2020 as part of their BXRX portfolio?

Baudax Bio launched ANJESO®, a non-opioid IV NSAID for managing moderate to severe pain.

When was ANJESO approved by the FDA for BXRX?

ANJESO was approved by the FDA on February 20, 2020, for the management of moderate to severe pain.

What are the benefits of ANJESO for patients according to BXRX's press release?

ANJESO addresses common issues associated with opioids, such as respiratory depression and addiction potential, while providing effective pain relief.